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The purpose of this study was to analyze the impact of graft-versus-host disease (GVHD) on the relapse rate of
different lymphoma subtypes after allogeneic hematopoietic cell transplantation (allo-HCT). Adult patients
with a diagnosis of Hodgkin lymphoma, diffuse large B cell lymphoma, follicular lymphoma (FL), peripheral T
cell lymphoma, or mantle cell lymphoma (MCL) undergoing HLA-identical sibling or unrelated donor he-
matopoietic cell transplantation between 1997 and 2009 were included. Two thousand six hundred eleven
cases were included. A reduced-intensity conditioning (RIC) regimen was used in 62.8% of the trans-
plantations. In a multivariate analysis of myeloablative cases (n ¼ 970), neither acute (aGVHD) nor chronic
GVHD (cGVHD) were signiﬁcantly associated with a lower incidence of relapse/progression in any lymphoma
subtype. In contrast, the analysis of RIC cases (n ¼ 1641) showed that cGVHD was associated with a lower
incidence of relapse/progression in FL (risk ratio [RR], .51; P ¼ .049) and in MCL (RR, .41; P ¼ .019). Patients
with FL or MCL developing both aGVHD and cGVHD had the lowest risk of relapse (RR, .14; P ¼ .007; and RR,
.15; P ¼ .0019, respectively). Of interest, the effect of GVHD on decreasing relapse was similar in patients with
sensitive disease and chemoresistant disease. Unfortunately, both aGVHD and cGVHD had a deleterious effect
on treatment-related mortality and overall survival (OS) in FL cases but did not affect treatment-related
mortality, OS or PFS in MCL. This study reinforces the use of RIC allo-HCT as a platform for immuno-
therapy in FL and MCL patients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION statistical center. Observational studies conducted by the CIBMTR are per-
A signiﬁcant number of patients with lymphoma are not
cured with conventional treatment or after high-dose ther-
apy and autologous transplantation. Allogeneic hematopoi-
etic cell transplantation (allo-HCT) is a potential curative
procedure for these patients because of the antilymphoma
effect of both the cytotoxic drugs in the conditioning regimen
and the immune attack mediated by the donor’s T cells.
Unfortunately, the conventional myeloablative conditioning
regimen (MAB) of allo-HCT is associated with high non-
relapse mortality (NRM) and, as a result, its role in the
therapeutic algorithm for lymphoma remains controversial
[1]. Furthermore, the average age of patients with the most
frequent subtypes of lymphoma is 60 to 65 years, an age
when MAB transplantations have prohibitive NRM. Allo-HCT
with a reduced-intensity conditioning (RIC) regimen is
associated with a lower rate of mortality and now represents
80% of all allo-HCT in some types of lymphoma [2]. RIC allo-
HCT transplantations would be an immunotherapy platform
for different subtypes of lymphoma, if a potent graft-versus-
lymphoma (GVLy) effect were demonstrated. The reported
clinical evidence of a GVLy effect is less robust than that
published for a graft-versus-leukemia effect. This may be
because of the relatively limited number of allo-HCT lym-
phoma cases reported in most series, as well as the fact that
different types of lymphoma are often analyzed together. The
main objectives of this study were to determine if graft-
versus-host disease (GVHD) was associated with a lower
relapse rate in speciﬁc subtypes of lymphomas and to
analyze whether this effect differs in MAB and RIC trans-
plantations. We hypothesized that the different biological
characteristics and growth kinetics between histological
subtypes might have a different impact of GVHD on relapse
rate. We also wanted to identify whether a potential
decreased relapse rate in patients developing GVHD would
result in an overall improved clinical outcome.PATIENTS AND METHODS
Data Source
The Center for International Blood and Marrow Transplant Research
(CIBMTR) (formerly IBMTR) is a combined research program of the Medical
College of Wisconsin and the National Marrow Donor Program. The CIBMTR
comprises a voluntary network of more than 450 transplantation centers
worldwide that contribute detailed data on consecutive allogeneic and
autologous hematopoietic cell transplantations (HCT) to a centralizedformed in compliance with all applicable US federal regulations pertaining
to the protection of human research participants. Protected health infor-
mation used in the performance of such research is collected and main-
tained in the CIBMTR capacity as a public health authority under the Health
Insurance Portability and Accountability Act Privacy rule. Additional details
regarding the data source are described elsewhere [3].
Patients
We analyzed 2611 cases of patients older than 18 years old who were
undergoing HLA-identical sibling or unrelated-donor HCT for lymphoma
reported to the CIBMTR between 1997 and 2009. Lymphoma types were
categorized as Hodgkin lymphoma (HL) (n ¼ 466), diffuse large B cell
lymphoma (DLBCL) (n¼ 579), follicular lymphoma (FL) (n¼ 871), peripheral
T cell lymphoma (PTCL) (n ¼ 195), and mantle cell lymphoma (MCL) (n ¼
500). Patients who received cord blood and ex vivo T celledepleted grafts
were excluded.
Study Endpoints
The main goal of this study was to compare the association of GVHD
with relapse rates in patients with different lymphoma subtypes and to
analyze whether this association differs in MAB and RIC/nonmyeloablative
(NMA) [4]. We also analyzed the impact of GVHD on NRM, overall survival
(OS), and progression-free survival (PFS). Acute and chronic GVHD (aGVHD
and cGVHD, respectively) were deﬁned as the occurrence of grade II, III, or IV
skin, gastrointestinal, or liver abnormalities that fulﬁll the consensus criteria
of aGVHD [5] and limited and extensive cGVHD [6], respectively. NRM was
deﬁned as death after transplantationwithout relapse or progression, where
relapse and progression were competing risks. Those patients who survived
without recurrence or progressionwere censored at the time of last contact.
OSwas deﬁned as time from transplantation to death. Death from any cause
was considered an event. PFS was deﬁned as survival after transplantation
without recurrence or lymphoma progression. Recurrence or progression of
the disease and death were counted as events. Those patients receiving
donor lymphocyte infusions (DLI) were censored when receiving the ﬁrst
dose. Those patients who survived without recurrence or progression were
censored at the time of last contact.
Statistical Analysis
Multivariate analyses were performed using Cox proportional hazards
models. A stepwise model building approach was used to identify the
signiﬁcant risk factors associated with the outcomes of relapse/progres-
sion, NRM, PFS, and OS. The assumption of proportional hazards for each
factor in the Coxmodel was tested using time-dependent covariates. When
the test indicated differential effects over time (nonproportional hazards),
models were constructed breaking the post-transplantation time course
into 2 periods, using the maximized partial likelihood method to ﬁnd the
most appropriate breakpoint. The proportionality assumptions were
further tested. A backward stepwise model selection approach was used to
identify all signiﬁcant risk factors. The main-effect variable was deﬁned as
the time-dependent occurrence of aGVHD only versus aGVHD þ cGVHD
versus cGVHD only versus neither. Each step of model building included
the main “treatment” effect. Factors that were signiﬁcant at a level of 5%
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effect and all signiﬁcant risk factors were tested. The effect of GVHD on the
relapse rate with 95% conﬁdence intervals (CI) were reported for each
lymphoma subtype and compared between lymphoma subtypes. Variables
considered in the multivariate models are as follows: patient-related (age
at transplantation, sex, and Karnofsky performance status at trans-
plantation), disease-related (lymphoma histology, disease stage at diag-
nosis, B symptoms at diagnosis, number of lines of chemotherapy before
transplantation, disease status at transplantation, and rituximab before
transplantation), and transplantation-related (interval from diagnosis to
transplantation, prior autologous transplantation, interval from autolo-
gous to allogeneic, donor-recipient cytomegalovirus status, donor-
recipient sex match, conditioning regimen, donor type, graft type, year
of transplantation, antithymocyte globulin/alemtuzumab, and GVHD pro-
phylaxis). To clarify whether the effect of GVHD on decreasing relapse if
present was in both sensitive and chemoresistant cases, we performed a
multivariate analysis in which the main variable of interest was GVHD and
the main outcome was relapse/progression. If in the multivariate analysis,
disease status independently inﬂuenced relapse/progression, we then
performed an interaction analysis to see precisely whether GVHD had a
different effect in the group of patients with sensitive disease versus thoseTable 1
Patient Demographics and Clinical Characteristics
Variable HL DL
No. of patients 466 57
Age at transplantation, median (range), yr 32 (18-69) 4
Sex
Male 278 (60) 33
Female 188 (40) 24
Karnofsky score
<90% 138 (30) 22
90% 288 (62) 32
Missing 40 (9) 3
No. of prior chemotherapy lines, median 4 4
Rituximab before transplantation
Yes 25 (5) 30
No 441 (95) 27
Disease status before transplantation
Chemosensitive 287 (62) 33
Chemoresistant 166 (36) 20
Missing 13 (3) 3
Interval from diagnosis to transplantation, mo 36 (5-413) 2
Prior autologous transplantation
No 155 (33) 43
Yes 311 (67) 14
Interval from autologous to allo, mo 36 (5-413) 2
Type of donor
HLA-identical sibling 100 (21) 23
URD well-matched 219 (47) 21
URD partially matched 117 (25) 9
URD mismatched 24 (5) 2
UNR unknown 6 (1) 1
Conditioning intensity
MAB 123 (26) 26
RIC 261 (56) 22
NMA 82 (18) 8
Graft type
Bone marrow 115 (25) 15
Peripheral blood 351 (75) 42
Year of transplantation
1997-2000 56 (12) 12
2001-2004 180 (39) 18
2005-2009 230 (49) 27
ATG/alemtuzumab
ATG þ alemtuzumab 1 (<1) 0
ATG alone 119 (26) 12
Alemtuzumab alone 40 (9) 4
No ATG or alemtuzumab 304 (65) 38
Missing 2 (<1) 1
GVHD prophylaxis
Tacrolimus  others 273 (59) 31
Cyclosporine  others 182 (39) 24
Other GVHD prophylaxis 11 (3) 2
Follow-up of survivors, median (range), mo 61 (3-170) 5
URD indicates unrelated donor; UNR, unrelated; ATG, antithymocyte globulin.patients with chemoresistant disease. A day 180 post-HCT landmark
analysis method was also used to compute the cumulative incidence of
relapse/progression in patients who had aGVHD and/or cGVHD versus
without aGVHD or cGVHD.
RESULTS
Patient Characteristics
Patient characteristics are shown in Table 1. The median
patient age was younger for patients with HL, with a male
predominance in MCL and PTCL. There were no differences
with respect to the proportion of patients with chemo-
sensitive versus chemoresistant disease. A higher proportion
of patients with HL had undergone a prior autologous
transplantation. More patients in the HL group had received
an unrelated donor transplant compared with the rest of the
patients. There were no differences in the use of antithy-
mocyte globulin/alemtuzumab or in post-transplantation
GVHD prophylaxis between lymphoma subgroups.BCL FL PTCL MCL
9 871 195 500
9 (18-70) 49 (21-70) 45 (18-69) 56 (23-75)
8 (58) 506 (58) 139 (71) 411 (82)
1 (42) 365 (42) 56 (29) 89 (18)
1 (38) 245 (28) 76 (39) 145 (29)
5 (56) 592 (68) 111 (57) 322 (64)
3 (6) 34 (4) 8 (4) 33 (7)
3 3 3
2 (52) 486 (56) 6 (3) 279 (56)
7 (48) 385 (44) 189 (97) 221 (44)
9 (59) 589 (68) 126 (65) 359 (72)
2 (35) 243 (28) 61 (31) 108 (22)
8 (7) 39 (4) 8 (4) 33 (7)
0 (2-309) 38 (1-352) 13 (2-159) 26 (3-175)
1 (74) 775 (89) 170 (87) 405 (81)
8 (26) 96 (11) 25 (13) 95 (19)
0 (2-309) 38 (1-352) 13 (2-159) 26 (3-175)
1 (40) 461 (53) 89 (46) 213 (43)
8 (38) 254 (29) 69 (35) 202 (40)
4 (16) 100 (11) 24 (12) 63 (13)
2 (4) 19 (2) 5 (3) 8 (2)
4 (2) 37 (4) 8 (5) 14 (3)
8 (46) 331 (38) 99 (51) 149 (30)
4 (39) 307 (35) 64 (33) 177 (35)
7 (15) 233 (27) 32 (16) 174 (35)
3 (26) 216 (25) 33 (17) 92 (18)
6 (74) 655 (75) 162 (83) 408 (82)
0 (21) 202 (23) 11 (6) 84 (17)
8 (32) 320 (37) 61 (31) 171 (34)
1 (47) 349 (40) 123 (63) 245 (49)
0 0 1 (<1)
6 (22) 144 (17) 35 (18) 103 (21)
8 (8) 67 (8) 18 (9) 58 (12)
9 (67) 649 (75) 139 (71) 324 (65)
6 (3) 11 (1) 3 (2) 14 (3)
2 (54) 444 (51) 107 (55) 259 (52)
6 (42) 390 (45) 79 (41) 229 (46)
1 (4) 37 (5) 9 (6) 12 (2)
7 (3-170) 63 (3-175) 48 (3-161) 60 (3-168)
Table 2
Univariate Analyses*
Outcomes HL DLBCL FL PTCL MCL P Valuey
aGVHD 40 (36-44) 35 (31-39) 34 (31-37) 39 (32-46) 36 (32-40) .208
cGVHD 47 (43-52) 33 (29-37) 45 (42-49) 49 (41-56) 43 (38-47) <.001
NRM 41 (36-46) 47 (43-51) 36 (33-39) 38 (31-46) 43 (39-48) .001
Relapse/progression 38 (34-43) 31 (27-34) 14 (12-17) 32 (25-39) 25 (21-29) <.001
PFS 21 (17-25) 22 (19-26) 50 (47-54) 30 (23-37) 32 (27-36) <.001z
OS 29 (25-33) 24 (21-28) 56 (53-59) 37 (29-45) 41 (36-45) <.001z
* Probabilities of aGVHD (at 100 days), cGVHD (at 1 year), NRM and relapse/progression (both at 5 years) were calculated using the cumulative incidence
estimate. PFS and OS (both at 5 years) were calculated using the Kaplan-Meier product limit estimate.
y Pointwise test.
z Log-rank test.
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Transplantation outcomes are shown in Table 2. OS at 5
years was better for patients with FL and MCL than for those
with HL and DLBCL. Similarly, 5-year PFS was better for those
with FL compared with the rest of the patients (Figures 1 and
2). The 5-year cumulative incidence of relapse was also
different between lymphoma subgroups (Figure 3). There
was no signiﬁcant difference between the lymphoma sub-
groups in the 100-day cumulative incidence of aGVHD grades
II to IV. The rate of 1-year cGVHD was not signiﬁcantly
different for patients with HL, FL, PTCL, and MCL, but it was
lower for those with DLBCL.
Association of acute and chronic GVHD on the Incidence
of Relapse/Progression
We ﬁrst examined the effects of GVHD in the entire cohort
(n ¼ 2611). In a multivariate analysis, cGVHD was associated
with a lower risk of relapse/progression in MCL (risk ratio
[RR], .41; 95% CI .21 to .80; P ¼ .009), but not in the other
lymphoma subtypes (Supplementary Table 1).
We next looked at the association of GVHD with relapse/
progression in 2 different groups, according to the intensity of
the conditioning regimen: MAB and RIC/NMA. In patients
who underwent transplantation with MAB, neither aGVHD
nor cGVHD were signiﬁcantly associated with a lower risk of
relapse/progression in any type of lymphoma. In contrast, in
patients who underwent transplantation with RIC/NMA
regimens (n ¼ 1641), cGVHD was associated with a lower
incidence of relapse/progression in thosewith FL (RR, .51; P¼
.049) and in those with MCL (RR, .41; P ¼ .019). Patients with
FL and MCL developing both aGVHD and cGVHD had the
lowest risk of relapse (RR, .12; 95% CI, .03 to .49; P¼ .003, and
RR, .14; 95% CI, .04 to .49; P¼ .0019, respectively) (Tables 3 and





















Figure 1. Overall survival of the different lymphoma subtypes, in the overall
group.depending on whether the group was either chemosensitive
or chemoresistant, which was performed for the overall
group, for MAB, and for RIC transplantations. Of interest, the
effect of GVHD on decreasing relapse was similar in patients
with sensitive disease and chemoresistant disease (see
interaction analysis results at the bottom of Tables 3 and 4).
To obtain a graphical illustration of the association of
GVHD on relapse rate in RIC allo-HCT in FL and MCL, we
performed a day 180 landmark study. Three hundred and
sixty-seven of 540 FL cases and 208 of 351MCL cases fulﬁlled
the conditions of being alive and in remission at 180 days
after transplantation. Results from the landmark analysis
were very similar to those observed in the multivariate
analysis, and, thus, those patients with FL and MCL devel-
oping both aGVHD and cGVHD had the lowest risk of relapse,
those developing either aGVHD or cGVHD had an interme-
diate risk of relapse, and those patients developing neither
aGVHD nor cGVHD had the highest risk of relapse (Figure 4).
Impact of acute and chronic GVHD on OS, NRM, and PFS
GVHD was reported as the primary cause of death in 13%
of the cases in HL, 10% in DLBCL, 17% in FL, 13% in PTCL, and
15% in MCL (Table 5). In a time-dependent multivariate
analysis, aGVHD was associated with inferior OS and NRM
in all lymphoma subtypes. When analyzed in the 2 speciﬁc
lymphoma groups in which GVHD was associated with
lower relapse, ie, patients with FL and MCL who underwent
RIC/NMA transplantations, both aGVHD and cGVHD had a
deleterious effect on NRM and OS in FL cases and did not
impact NRM, OS or PFS in MCL (Supplementary Table 2).
DISCUSSION
A potential clinical impact of GVLy in FL andMCL has been
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Figure 3. Cumulative incidence of relapse per lymphoma subtype in the overall group (A), in myeloablative conditioning (B), and in reduced-intensity conditioning (C).
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FL who underwent allo-HCT compared with those receiving
an autologous HCT [8,9], but they did not ﬁnd any association
between aGVHD or cGVHD and recurrence after allo-HCT.
Here we show, for the ﬁrst time, in a very large series of FLTable 3
Multivariate Analysis of the Inﬂuence of GVHD on Relapse/Progression in
Mantle Cell and Follicular Lymphoma (acute GVHD II to IV)
Risk Factor RR (95% CI) P Value
MAB allo-HCT
MCL (n ¼ 149)*
aGVHD II-IV 1.51 (.37-6.12) .56
cGVHD .42 (.08-2.19) .30
aGVHD II-IV þ cGVHD versus no GVHD 1.32 (.23-7.49) .75
Disease status
Sensitive 1.00
Resistant 2.51 (1.02-6.18) .05
Missing 3.12 (1.17-8.34) .024
FL (n ¼ 331)y
aGVHD II-IV .87 (.17-4.56) .87
cGVHD 1.22 (.34-4.40) .76
aGVHD II-IV þ cGVHD versus no GVHD 1.34 (.35-5.10) .67
Disease status
Sensitive 1.00
Resistant 3.20 (1.54-6.66) .002
Missing 1.29 (.17-10.04) .81
RIC/NMA allo-HCTz
MCL (n ¼ 351)
aGVHD II-IV 1.04 (.49-2.19) .92
cGVHD .41 (.20-.86) .019
aGVHD II-IV þ cGVHD versus no GVHD .15 (.04-.50) .002
Disease status
Sensitive 1.00
Resistant 1.96 (1.22-3.15) .006
Missing .15 (.02-1.06) .057
FL (n ¼ 540)x
aGVHD II-IV .46 (.16-1.28) .14
cGVHD .51 (.26-.99) .049
aGVHD II-IV þ cGVHD versus no GVHD .14 (.03-.58) .007
* Interaction test between GVHD disease status (P ¼ .79). Three-degree
freedom test.
y Interaction test between GVHD disease status (P ¼ .45). Three-degree
freedom test.
z Interaction test between GVHD disease status (P ¼ .36). Three-degree
freedom test.
x Disease status was not signiﬁcant.patients who underwent allo-HCT, an association between
GVHD and a lower relapse rate. As far as MCL is concerned, 1
study [10] suggested a lower relapse rate after allo-HCT than
after autologous HCT. In the univariate analysis, patients with
cGVHD had a lower actuarial probability of relapse thanTable 4
Multivariate Analysis of the Inﬂuence of GVHD on Relapse/Progression in
Mantle Cell and Follicular Lymphoma (acute GVHD III and IV)
RR (95% CI) P Value
MAB allo-HCT*
MCL (n ¼ 149)
aGVHD III-IV 1.66 (.33-8.41) .54
cGVHD .66 (.14-3.22) .61





Resistant 2.52 (1.03-6.17) .044
Missing 3.17 (1.18-8.50) .022
FL (n ¼ 331)y
aGVHD III-IV 1.47 (.40-5.44) .56
cGVHD .65 (.22-1.93) .44
Disease status
Sensitive 1.00
Resistant 3.30 (1.58-6.90) .002
Missing 1.21 (.16-9.35) .86
RIC/NMA allo-HCTz
MCL (n ¼ 351)
aGVHD III-IV .98 (.44-2.15) .94
cGVHD .27 (.11-.66) .004





Resistant 1.88 (1.16-3.04) .010
Missing .15 (.02-1.08) .060
FL (n ¼ 540)x
aGVHD III-IV .24 (.06-.99) .049
cGVHD .43 (.21-.87) .018
* Interaction test between GVHD disease status (P ¼ .79). Three-degree
freedom test.
y Interaction test between GVHD disease status (P ¼ .45). Three-degree
freedom test.
z Interaction test between GVHD disease status (P ¼ .36). Three-degree
freedom test.
x Disease status was not signiﬁcant.
Figure 4. Landmark analysis at 180 days after RIC allo-HCT showing the cumulative incidence of relapse in patients who had: (1) no acute GVHD, no chronic GVHD
(AG-N/CG-N); (2) acute GVHD, no chronic GVHD (AG-Y/CG-N); (3) no acute GVHD, chronic GVHD (AG-N/CG-Y); and (4) both acute GVHD and chronic GVHD (AG-Y/
CG-Y) in (left) mantle cell lymphoma and in (right) follicular lymphoma.
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variate analysis was not performed, and competing risks
were not taken into consideration. Here, we demonstrate
a strong association of cGVHD with decreased relapse after
allo-HCT for MCL analyzed in a multivariate study, consid-
ering cGVHD as a time-dependent variable. This is in line
with studies showing a high relapse rate of MCL after allo-
HCT when donor T cells are eliminated from the graft
[11,12]. Thus, we suggest an important role of GVLy in
reducing relapse rates in FL and MCL. A landmark analysis
conﬁrmed the effect of GVHD on the relapse rate in FL and
MCL. Thus, as also was observed in the multivariate analysis,
patients with FL and MCL developing both aGVHD and
cGVHD had the lowest risk of relapse (Figure 4). Of interest,
the effect of GVHD on decreasing relapse was similar in pa-
tients with sensitive disease and chemoresistant disease
(Tables 3 and 4, interaction analysis).
An intriguing result from this study is that the association
of GVHD and decreased relapse in FL and MCL lymphoma
was observed only in allo-HCT performed with RIC/NMA
regimens and not after MAB transplantations. One may
speculate that the more intense MAB regimen already pro-
vides a signiﬁcantly more cytotoxic, antilymphoma effect
than the RIC/NMA regimen, making the addition of an allo-
geneic effect less obvious. From a clinical point of view, this
disparity may have little relevance, as the vast majority of
lymphoma patients now receive a RIC/NMA regimen as part
of their allo-HCT. From a biological point of view, this pecu-
liarity is difﬁcult to explain because the effect of alloreactiveTable 5
Causes of Death
Cause of Death HL DLBCL
No. of deaths 331 433
Graft rejection 1 (<1) 1 (<1
Infection 46 (14) 70 (16
IpN 9 (3) 22 (5)
ARDS 7 (2) 12 (3)
GVHD 44 (13) 43 (10
Primary disease 147 (44) 187 (43
Organ failure 33 (10) 58 (13
Second malignancy 2 (1) 1 (<1
Hemorrhage 8 (2) 11 (3)
Accidental death 1 (<1) 0
Vascular 6 (2) 2 (<1
Toxicity 10 (3) 9 (2)
Other: not speciﬁed/unknown 17 (5) 17 (4)
IpN indicates interstitial pneumonia; ARDS, acute respiratory distress syndrome.T cells developing both GVHD and GVLy should be similar,
regardless of the intensity of the conditioning regimen. This
differencemight also be statistically justiﬁed. Thus, the initial
smaller sample size for MAB transplantations than for RIC/
NMA transplantations and the fact that more patients in the
MAB group died early after allo-HCTmay have led to a poorer
detection of associations of GVHD and lower relapse. Similar
observations of an association of GVHD on a decreasing
relapse rate in RIC/NMA, but not in MAB allo-HCT, have also
been described in acute myeloblastic leukemia and in mye-
lodysplastic syndromes [13,14].
In this study we did not observe an association between
GVHD and a lower rate of relapse in DLBCL. This is in line
with previous studies showing that relapse after autologous
HCT for DLBCL patients is quite similar to that after allo-HCT
[15,16]. However, allo-HCT may be a salvage therapy for pa-
tients with DLBCL relapsing after an autologous HCT [17,18].
For HL, in 1996 the European Society for Blood and Marrow
Transplantation (EBMT) published a report showing a lower
relapse rate after MAB allo-HCT than after autologous HCT,
but this was offset by a very high NRM associated with MAB
[19]. More recently, in a multivariate analysis, the EBMT has
not found an association of GVHD with relapse rate in
patients with HL who underwent RIC [20], although in a
landmark analysis, patients with cGVHD had a lower inci-
dence of relapse. In the present study, which included a
much larger number of patients, we did not observe an as-
sociation of GVHD with a lower relapse rate in those with HL
using a Cox model, in line with the EBMT results. If theseFL PTCL MCL
403 112 293
) 1 (<1) 0 1 (<1)
) 80 (20) 22 (20) 49 (17)
24 (6) 3 (3) 9 (3)
10 (2) 1 (1) 12 (4)
) 69 (17) 15 (13) 43 (15)
) 79 (20) 41 (37) 90 (31)
) 67 (17) 20 (18) 43 (15)
) 12 (3) 0 6 (2)
10 (2) 4 (4) 11 (4)
2 (<1) 0 2 (1)
) 6 (1) 2 (2) 5 (2)
18 (4) 1 (1) 10 (3)
25 (6) 3 (3) 12 (4)
A. Urbano-Ispizua et al. / Biol Blood Marrow Transplant 21 (2015) 1746e17531752results are conﬁrmed in other studies, allo-HCT for DLBCL
and HL should be only offered within the context of a clinical
trial designed to improve the GVLy effect. As far as PTCL is
concerned, we were not able to demonstrate a relationship
between GVHD and a lower rate of relapse. The low number
of patients with this disease included in the study precludes
us from drawing ﬁrm conclusions.
The association of GVHD with lower relapse rate herein
observed in FL and MCL, but not in DLBCL, HL, and PTCL, are
in line with results observed in short series of lymphoma
patients treated with DLI. There are at least 3 studies
showing a potent effect of DLI to treat FL and MCL relapses
after allo-HCT [12,21,22]. In contrast, DLI seem to have very
limited activity as a salvage treatment for patients with
DLBCL relapsing after allo-HCT [23]. Results of DLI in HL and
PTCL [16,24,25] are more encouraging, without achieving the
excellent results obtained in FL and MCL lymphoma. Thus,
DLI is very effective in FL and MCL, of moderate effect in HL
and PTCL, and very limited in DLBCL. These, together with
our own results, support the presence of a strong GVLy effect
after allo-HCT in FL and MCL. The low proliferation rate of
indolent lymphomas might be 1 reason that explains an
effective role of the donor’s immune system to control tumor
growth in these lymphoma subtypes.
The beneﬁcial effect of GVHD on a lower relapse rate in FL
and MCL did not translate into an overall clinical outcome
advantage. This negative impact of GVHD, despite decreasing
the relapse rate, as has been reported in other diseases
[14,26]. Strategies combining attenuation of GVHD with
post-HCT treatment maintenance and potentiating the GVLy
effect, with late DLI or chimeric antigen receptoremodiﬁed T
cells [27], could improve the clinical outcome of FL and MCL
patients undergoing RIC allo-HCT.
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